세계의 의약품 용출 시장 : 유형별, 최종 사용자별, 지역별 분석 및 예측(2024-2033년)

This report can be delivered within 1 working day.

Introduction of Pharmaceutical Dissolution

Pharmaceutical dissolution is the process in which a drug, typically in the form of a tablet, capsule, or powder, dissolves in a liquid, usually a simulated bodily fluid, to release its active pharmaceutical ingredient (API). This process is vital for understanding how a drug functions within the body, as it influences the drug's bioavailability and how quickly and to what extent the active ingredient is absorbed into the bloodstream. Dissolution testing plays a critical role in pharmaceutical development and quality assurance, ensuring that the drug formulation is safe, effective, and consistent when used by patients. It is essential for evaluating and refining oral dosage forms and providing necessary data for drug approval and regulatory compliance.

Market Introduction

The global pharmaceutical dissolution market is expected to witness significant expansion, projected to reach $1,311.2 million by 2035.

The pharmaceutical dissolution market plays a key role in drug development, formulation, and ensuring quality. As regulatory requirements increase, technological innovations advance, and there is a greater emphasis on enhancing patient outcomes, the market is set for significant growth and evolution in the coming years. Pharmaceutical dissolution refers to the process by which a drug dissolves in a solvent, typically water or gastric fluids, allowing it to be absorbed into the bloodstream. This is a crucial phase in the pharmacokinetics of oral medications as it determines the rate and extent to which the active pharmaceutical ingredient (API) becomes available for absorption. The dissolution rate of a drug affects its bioavailability, therapeutic effectiveness, and overall clinical performance. In pharmaceutical product development, dissolution testing is a standardized method used to assess the release of drugs from dosage forms like tablets, capsules, or suspensions. Regulatory agencies, such as the FDA, require this testing to ensure that drug products consistently perform as intended, maintaining quality and safety standards.

The pharmaceutical dissolution ecosystem is undergoing rapid innovation, driven by technological advancements, regulatory demands, and evolving drug development strategies. As dissolution testing continues to evolve with the integration of automation, AI, and real-time monitoring, it is poised to play an even more critical role in ensuring the success of pharmaceutical products in the global market. Analysts are increasingly recognizing dissolution testing not just as a regulatory requirement, but as a vital component of the drug development pipeline, helping to ensure both the efficacy and safety of new medications while supporting the ongoing shift toward more personalized and complex therapies.

Pharmaceutical dissolution ecosystem is multi-faceted in nature and involves various stakeholders that are involved in contributing towards market growth:

Product Manufacturers: At the heart of the dissolution testing market, pharmaceutical companies generate demand for testing services and equipment. They play a crucial role in carrying out dissolution testing throughout the stages of drug development, manufacturing, and quality assurance. For instance, Agilent Technologies, Inc. is at the forefront of driving the pharmaceutical dissolution market with expanding its dissolution business.

Service Providers: Contract Research Organizations (CROs) offer testing and research services to pharmaceutical companies, including dissolution testing. They are especially valuable for companies that lack the in-house expertise or resources to perform this specialized work.

Regulatory Authorities: Regulatory bodies such as the US FDA, EMA, and other national and international regulatory authority are involved in setting the regulatory standards and guidelines for pharmaceutical dissolution testing, certifying that dissolution testing products are under compliance.

Industrial Impact

The pharmaceutical industry's impact on various sectors is vast and multifaceted, affecting public health, economics, employment, and technological innovation.

Impact: Dissolution testing is crucial for ensuring the quality and consistency of pharmaceutical products. It helps verify that a drug's active pharmaceutical ingredient (API) is released at the correct rate and in the appropriate quantity, as expected under specific conditions. This is essential for ensuring that the drug performs consistently across different batches. Any variability in dissolution rates could lead to inconsistent drug efficacy, which could impact patient safety. Thus, dissolution testing forms a core part of quality control in pharmaceutical manufacturing, ensuring that products meet strict regulatory standards.

Regulatory bodies such as the FDA, EMA, and WHO have established strict dissolution testing protocols to ensure that drugs meet safety and performance criteria before being marketed. Pharmaceutical companies must demonstrate that their products dissolve appropriately for the API to be absorbed in the body, and this must be proven in dissolution testing. This is particularly important for oral solid dosage forms like tablets and capsules, where the dissolution profile directly affects bioavailability. For example, in the U.S., the FDA's guidance on dissolution testing for immediate-release and extended-release formulations ensures that pharmaceutical companies adhere to scientifically validated methods to assess how the drug is released in a simulated biological environment.

Market Segmentation:

Segmentation 1: By Type

• Product
  • Dissolution System
  • Dissolution Accessories
• Services

Product type remains the leading segment by type in the global pharmaceutical dissolution market, holding an 63.43% market share in 2024, with a projected CAGR of 8.57% during the forecast period 2024-2033.

The dominance of products i.e. dissolution systems and their accessories in the pharmaceutical market is primarily driven by their critical role in ensuring drug quality, patient safety, and regulatory compliance. With ongoing advancements in technology, precision, and sustainability, these products continue to meet the evolving needs of pharmaceutical development, manufacturing, and global market dynamics. The continuous focus on quality assurance, therapeutic efficacy, cost-effectiveness, and regulatory standards ensures that dissolution systems will remain a cornerstone of the pharmaceutical industry for the foreseeable future.

Segmentation 2: By End User

• Pharmaceutical and Biotechnology Companies
• CROs
• Academic Institutions

Based on end user, pharmaceutical and biotechnology companies is dominating the pharmaceutical dissolution market, which accounted for 48.57% of the global market. Pharmaceutical and biotechnology companies engaged in dissolution testing focus on developing, producing, and marketing drug products that dissolve at the proper rate, ensuring the controlled and consistent release of active pharmaceutical ingredients (APIs). This testing is essential during the development of new drug formulations and plays a vital role in quality control within pharmaceutical manufacturing. is essential during the development of new drug formulations and plays a vital role in quality control within pharmaceutical manufacturing.

Segmentation 3: By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia-Pacific
  • Japan
  • India
  • China
  • Rest-of-Asia-Pacific
• Latin America
• MEA

North America dominates the global pharmaceutical dissolution market, holding the largest market share. This growth has been driven by significant advancements in drug formulations, increased regulatory scrutiny, and the growing adoption of dissolution testing in pharmaceutical research and development (R&D) as well as manufacturing processes. The region is highly competitive, with a mix of international and regional players offering a wide range of products and services. Prominent market players include Agilent Technologies, SOTAX, Distek, Inc., and Catalent Inc., among others.

The U.S. pharmaceutical dissolution market has been experiencing robust growth, fueled by several key factors, including the rising demand for generic drugs, stringent regulatory standards, technological innovations, the increasing complexity of drug formulations, and the growing trend of outsourcing. Together, these elements highlight the essential role that dissolution testing plays in ensuring pharmaceutical products' safety, efficacy, and regulatory compliance as companies address an evolving and increasingly complex regulatory environment

The pharmaceutical dissolution market in the Asia-Pacific region has been witnessing continuous growth owing to the rising demand for pharmaceutical products and stringent regulatory standards. Despite several challenges in the pharmaceutical dissolution market in Asian countries, such as regulatory complexity, infrastructure gaps, and a shortage of workforce, the market is advancing due to technological advancements, the rise of generics, and increased focus on quality control. As pharmaceutical manufacturing continues to expand in the region, the need for accurate and efficient dissolution testing will be critical in ensuring the safety and efficacy of oral medications.

Recent Developments in the Pharmaceutical Dissolution Market

• In May 2024, Logan Instrument launched the "EPVT-1200 system" for USP apparatus 1 and 2 performance validation tests, focused on revolutionizing dissolution testers' validation process. This innovative digital toolset performs and records dissolution validation performance electronically, thereby eliminating the uncertainties associated with manual recording methods.
• In August 2024, Logan Instruments Corp. unveiled its newest innovation, the Microsphere Release Testing System. This groundbreaking product is designed to transform the testing and development processes for microsphere dosage forms, meeting the increasing demand for advanced drug delivery solutions.

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

• Expanding Pharmaceutical Manufacturing Facilities Leading to Increased Demand for Dissolution Testing

Dissolution testing is essential for ensuring the quality, safety, and efficacy of pharmaceutical products. As manufacturing facilities expand and increase production to meet the growing global demand, particularly in emerging markets, the need to evaluate the dissolution properties of oral solid dosage forms such as tablets and capsules becomes pronounced. Additionally, dissolution testing is crucial for ensuring that drugs comply with regulatory standards and perform as intended, leading to heightened demand for testing infrastructure within expanding manufacturing facilities.

Major juggernauts in the pharmaceutical industry are involved in opening new facilities to aid R&D activities and growing their manufacturing footprint. For instance, in April 2024, Thermo Fisher Scientific opened a new sterile drug production facility in Singapore to aid in the research, development, and manufacturing of medicines and vaccines for the Asia-Pacific market. This cGMP-compliant facility is expected to provide vaccine fill-finish services, enhancing companies' existing pharmaceutical development and production capabilities.

Dissolution testing is an essential component of pharmaceutical manufacturing, used to evaluate the rate at which active pharmaceutical ingredients (APIs) are released from tablets, capsules, or other solid dosage forms into a solution. This process is crucial for determining bioavailability and ensuring the therapeutic effectiveness of the medication.

Some of the other factors creating an drivers for market growth include:

• Integration of Personalized Medicine in Pharmaceutical Dissolution Market

Note: All of the above factors will be evaluated in detail in the report.

Market Restraints:

• Entry Barrier for New Entrants in Pharmaceutical Dissolution Market

Capital Requirement: Establishing manufacturing and testing facilities equipped for dissolution testing requires significant capital investment. For instance, for a small to mid-sized laboratory performing pharmaceutical dissolution testing, an approximate initial capital investment ranges from $50,000 to $200,000 for basic setups, and costs can increase to $500,000 or more for automated, high-throughput systems with integrated analysis tools. Such high capital requirements are unaffordable for small or mid-sized companies in the pharmaceutical dissolution market. Furthermore, the expenses involved in sourcing high-quality raw materials and developing a skilled workforce add to the financial burden.

Established Competition from Major Players: The pharmaceutical dissolution market is a competitive market such as Agilent Technologies, Inc., Distek, Inc., Sotax, Catalent, and Charles River Laboratories. The market is largely controlled by established companies with strong brand recognition, a broad customer base, and a comprehensive range of products and services. Challenging these dominant players is difficult, as new entrants must find ways to distinguish themselves through innovation, higher quality, or better cost-efficiency to capture market share.

Note: All of the above factors will be evaluated in detail in the report.

Market Opportunities: Rising Implementation of AI And ML for Pharmaceutical Dissolution

Artificial intelligence (AI) and machine learning (ML) are transforming pharmaceutical development by improving efficiency, accuracy, and predictive capabilities across multiple stages, including dissolution testing. These cutting-edge technologies are progressively being incorporated into pharmaceutical research and development (R&D) to enhance drug formulation, streamline testing procedures, and more accurately forecast in vivo behavior.

AI can assess the interactions between formulate and drug components (such as excipients and active pharmaceutical ingredients) and their impact on dissolution rates. This capability enables the optimization of drug formulations to achieve the desired dissolution properties. Machine learning models can determine the optimal combination of ingredients and processing parameters to enhance drug release rates, thereby improving both the drug's efficacy and stability.

Furthermore, AI and ML are transforming drug manufacturing by enhancing process optimization, predictive maintenance, and quality control. AI-powered algorithms can analyze large datasets and uncover patterns that might be overlooked by humans, leading to improved efficiency and cost reductions.

Some of the other factors creating an opportunity for market growth include:

• Shift towards more sophisticated pharmaceutical dissolution testing

Note: All of the above factors will be evaluated in detail in the report.

Market Trends:

• Technological Advancements in Dissolution Testing Apparatus

Recent innovations in dissolution testing equipment, including automation, high-throughput systems, and real-time monitoring, are significantly improving the efficiency, precision, and reliability of testing processes. These advancements enable faster and more accurate measurement of drug release profiles, which is essential for both product development and regulatory compliance. Automation streamlines the testing process, reducing the risk of human error and increasing throughput, while high-throughput systems lead to simultaneous testing of multiple samples, speeding up the overall evaluation process. Moreover, real-time monitoring provides on-line data, offering deeper insights into the dissolution process and allowing for immediate adjustments if required.

These technological developments are transforming the landscape of dissolution testing by making it more efficient and cost-effective, ultimately profiting both pharmaceutical companies and regulatory agencies. As a result, there is a growing demand for suppliers of cutting-edge dissolution testing equipment and related technologies. Companies that offer advanced dissolution apparatus, software solutions, and integration services stand to capitalize on this trend, catering to the increasing need for faster, more accurate, and automated testing systems in the pharmaceutical industry.

Note: All of the above trends will be evaluated in detail in the report.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in pharmaceutical dissolution, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in pharmaceutical dissolution and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Pharmaceutical Dissolution, ensuring organizations stay compliant and accelerate market entry for new Pharmaceutical Dissolution

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2023-FY2033.
• The scope of this report has been carefully derived based on extensive interactions with experts and stakeholders across leading companies and research institutions worldwide. This report provides a comprehensive market of the Pharmaceutical Dissolution market.
• Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available Pharmaceutical Dissolution products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in Pharmaceutical Dissolution, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Validation of the numbers of the different segments of the market in focus
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

The global pharmaceutical dissolution market has been witnessing robust growth driven by the presence of regulatory bodies such as the U.S. FDA and EMA, which mandate dissolution testing to ensure the quality and bioavailability of pharmaceutical products, driving demand in the industry. The rise of generic drugs, which must demonstrate bioequivalence, further fuels the need for dissolution testing. Technological advancements, such as automation and real-time testing, enhance the speed, accuracy, and cost-effectiveness of these tests. Additionally, the increasing focus on R&D for new formulations, complex drug delivery systems, and biologics contributes to the market growth. As personalized medicine gains ground, specialized dissolution methods are becoming more crucial. The growing trend of outsourcing testing to CROs and CDMOs has also been supporting market expansion. These factors, along with a focus on drug safety and quality, are shaping the global pharmaceutical dissolution market.

Some prominent names established in this market are:

• Charles River Laboratories International, Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Cytiva)
• Sotax
• Distek, Inc.
• Agilent Technologies, Inc.
• Waters Corporation

Table of Contents

Executive Summary

1 Research Methodology

• 1.1 Data Sources
  • 1.1.1 Primary Data Sources
  • 1.1.2 Secondary Data Sources
  • 1.1.3 Data Triangulation
• 1.2 Market Estimation and Forecast

2 Global Pharmaceutical Dissolution Market: Overview

• 2.1 Definitions
  • 2.1.1 Product Definition
• 2.2 Inclusion and Exclusion Criteria
• 2.3 Key Findings

3 Market Industry Outlook

• 3.1 Market Overview and Ecosystem
• 3.2 Market Opportunities Assessment
• 3.3 Product Benchmarking
• 3.4 Regulatory Landscape/Compliances
  • 3.4.1 U.S.
  • 3.4.2 European Union (EU)
  • 3.4.3 Japan
  • 3.4.4 China
• 3.5 Membrane Adoption Analysis (by Type)
  • 3.5.1 Mixed Cellulose Ester (MCE)-based
  • 3.5.2 Polyvinylidene Fluoride (PVDF)-based
  • 3.5.3 Glass Fiber-based
  • 3.5.4 Nylon-based
  • 3.5.5 Polytetrafluoroethylene (PTFE)-based
  • 3.5.6 Others
• 3.6 Membrane-Type Penetration in Approved Dissolution Tests
• 3.7 Market Dynamics Overview
  • 3.7.1 Market Drivers
    • 3.7.1.1 Expanding Pharmaceutical Manufacturing Facilities Leading to Increased Demand for Dissolution Testing
    • 3.7.1.2 Integration of Personalized Medicine in Pharmaceutical Dissolution Market
    • 3.7.1.3 Role of Regulatory Standards in Shaping the Pharmaceutical Dissolution Market
  • 3.7.2 Market Restraints
    • 3.7.2.1 Presence of Alternative to Dissolution Testing
    • 3.7.2.2 Entry Barrier for New Entrants in Pharmaceutical Dissolution Market
    • 3.7.2.3 Various Challenges Faced by New Entrants
  • 3.7.3 Market Opportunities
    • 3.7.3.1 Rising Implementation of AI And ML for Pharmaceutical Dissolution
    • 3.7.3.2 Shift towards More Sophisticated Pharmaceutical Dissolution Testing
  • 3.7.4 Key Trends
    • 3.7.4.1 Technological Advancements in Dissolution Testing Apparatus
    • 3.7.4.2 Increasing Number of CROs and CDMOs Involved in Dissolution Testing
      • 3.7.4.2.1 Specialized Testing Services
      • 3.7.4.2.2 Quality Control of Drugs
      • 3.7.4.2.3 Adherence to Regulatory Standards during Dissolution Testing

4 Global Pharmaceutical Dissolution Market (by Type), $Million, 2023-2033

• 4.1 Growth Share Matrix
• 4.2 Product
• 4.3 Growth Share Matrix
  • 4.3.1 Dissolution System
    • 4.3.1.1 Manual Dissolution System
    • 4.3.1.2 Automated Dissolution System
    • 4.3.1.3 Semi-Automated Dissolution System
  • 4.3.2 Dissolution Accessories
    • 4.3.2.1 Filters
      • 4.3.2.1.1 Syringe Filters
      • 4.3.2.1.2 Cannula Filters/Full Flow Filters
      • 4.3.2.1.3 Hollow Fiber Filters
    • 4.3.2.2 Dissolution Vessels
    • 4.3.2.3 Dissolution Baskets and Paddles
    • 4.3.2.4 Other Accessories
• 4.4 Service

5 Global Pharmaceutical Dissolution Market (by End User), $Million, 2023-2033

• 5.1 Growth Share Matrix
• 5.2 Pharmaceutical and Biotechnology Companies
• 5.3 Contact Research Organizations (CROs)
• 5.4 Academic Institutions

6 Global Pharmaceutical Dissolution Market (By Region), $Million, 2023-2033

• 6.1 Regional Summary
• 6.2 Growth Share Matrix
• 6.3 North America
  • 6.3.1 Regional Overview
  • 6.3.2 Driver
    • 6.3.2.1 Stringent Regulatory Framework
    • 6.3.2.2 Advancement in Dissolution Testing
    • 6.3.2.3 Increasing Demand for Biologics and Biosimilars
    • 6.3.2.4 Increasing Investment in R&D
  • 6.3.3 Restraints
    • 6.3.3.1 High Cost Associated with Dissolution Testing
    • 6.3.3.2 Evolving Regulatory Landscape
  • 6.3.4 U.S.
    • 6.3.4.1 Growing Trend of Outsourcing
    • 6.3.4.2 Expansion of the Pharmaceutical Manufacturing Sector
    • 6.3.4.3 High Cost Associated with Dissolution Testing
  • 6.3.5 Canada
    • 6.3.5.1 Stringent Regulatory Framework
    • 6.3.5.2 Increasing Demand for Generic Drugs
    • 6.3.5.3 Rising Government Initiatives
    • 6.3.5.4 Shortage of Skilled Workforce
    • 6.3.5.5 Evolving Regulatory Requirements
• 6.4 Europe
  • 6.4.1 Regional Overview
  • 6.4.2 Drivers
    • 6.4.2.1 Stringent Regulatory Guidelines for Drug Approvals
    • 6.4.2.2 Growing Focus on Quality Assurance
    • 6.4.2.3 Technological Advancement in Dissolution Testing
  • 6.4.3 Restraints
    • 6.4.3.1 Discriminatory Power of Dissolution Methods
    • 6.4.3.2 Regulatory Complexity and Evolving Standards
  • 6.4.4 Germany
    • 6.4.4.1 Increasing Adoption of Generic Drugs
    • 6.4.4.2 Rising Interest in Biopharmaceuticals
    • 6.4.4.3 Growing Focus on Quality Assurance
    • 6.4.4.4 Shortage of Skilled Labor
    • 6.4.4.5 Rising Pressure on Cost Efficiency
  • 6.4.5 U.K.
    • 6.4.5.1 Shifting Trends toward Generic Drugs
    • 6.4.5.2 Innovation in Dissolution Testing Technologies
    • 6.4.5.3 Increasing Government Initiatives
    • 6.4.5.4 Challenges in Dissolution Testing
    • 6.4.5.5 Variability in Dissolution Tests Result
  • 6.4.6 France
    • 6.4.6.1 Increasing Demand for Generic Drugs
    • 6.4.6.2 High Emphasis on Quality Assurance
    • 6.4.6.3 Testing Complex Drug Formulations
    • 6.4.6.4 Technical Challenges in Biorelevant Dissolution Testing
  • 6.4.7 Italy
    • 6.4.7.1 Stringent Regulatory Guidelines for Drug Approvals
    • 6.4.7.2 Rising Focus on Complex Drug Formulation
    • 6.4.7.3 Long Approval Time
  • 6.4.8 Spain
    • 6.4.8.1 Rising Development in Biopharmaceutical Industry
    • 6.4.8.2 Focus on Regulatory Requirements
    • 6.4.8.3 Significant Vulnerabilities in the Pharmaceutical Dissolution Process
  • 6.4.9 Rest-of-Europe
    • 6.4.9.1 Government Funding and Support
    • 6.4.9.2 High Costs of Advanced Dissolution Testing Systems
    • 6.4.9.3 Technological Adoption in Emerging Markets
• 6.5 Asia-Pacific
  • 6.5.1 Regional Overview
  • 6.5.2 Drivers
    • 6.5.2.1 Expanding Pharmaceutical Manufacturing in Asian Countries
    • 6.5.2.2 Increasing Biopharmaceutical and Outsourcing Testing Services
  • 6.5.3 Restraints
    • 6.5.3.1 Lack of Advanced Dissolution Testing Facilities
    • 6.5.3.2 Shortage of Skilled Professionals
  • 6.5.4 China
    • 6.5.4.1 Expanding Pharmaceutical Industry
    • 6.5.4.2 Rising Demand for Generic Drugs
    • 6.5.4.3 High Competition from Low-Cost Markets
    • 6.5.4.4 Shortage of Skilled Workforce
  • 6.5.5 Japan
    • 6.5.5.1 Technological Advancements in Dissolution Testing
    • 6.5.5.2 Rising Focus on Drug Development
    • 6.5.5.3 Regulatory Standardization and Complexity
  • 6.5.6 India
    • 6.5.6.1 Growth in the Generic Drug Development
    • 6.5.6.2 Ease of Access to Outsourcing Dissolution Services
    • 6.5.6.3 Shortage of Skilled Workforce for Dissolution Procedure
  • 6.5.7 Rest-of-Asia-Pacific
    • 6.5.7.1 Growth in Pharmaceutical Manufacturing Facilities
    • 6.5.7.2 Counterfeit Drugs and Quality Control Concerns
• 6.6 Latin America
  • 6.6.1 Regional Overview
  • 6.6.2 Driver
    • 6.6.2.1 Availability of State-of-Art Pharmaceutical Dissolution Suppliers
    • 6.6.2.2 Outsourcing of Analytical Services by Pharmaceutical Companies
    • 6.6.2.3 Rising Pharmaceutical R&D in Latin America
  • 6.6.3 Restraints
    • 6.6.3.1 Limited Access to Dissolution Testing and Technologies
    • 6.6.3.2 Lack of in-house Dissolution Testing
• 6.7 Middle East and Africa (MEA)
  • 6.7.1 Regional Overview
  • 6.7.2 Driver
    • 6.7.2.1 Expansion of Pharmaceutical Manufacturing Facilities
    • 6.7.2.2 Rising Focus on Drug Development Formulation
  • 6.7.3 Restraints
    • 6.7.3.1 Lack of Advanced Infrastructure
    • 6.7.3.2 Shortage of Skilled Workforce for Dissolution Testing

7 Markets - Competitive Landscape

• 7.1 Competitive Benchmarking
• 7.2 Competitive Landscape
  • 7.2.1 Corporate Strategies, January 2021-September 2024
  • 7.2.2 Business Expansions
  • 7.2.3 Mergers and Acquisitions
  • 7.2.4 Funding Activities
  • 7.2.5 Regulatory Approval and Product Launch January 2021-September 2024
  • 7.2.6 Key Developments Analysis
  • 7.2.7 Company Share Analysis, 2023
    • 7.2.7.1 Dissolution System
    • 7.2.7.2 Dissolution Accessories
• 7.3 Company Profiles (Major Manufacturers)
  • 7.3.1 Agilent Technologies, Inc.
    • 7.3.1.1 Overview
    • 7.3.1.2 Top Products
      • 7.3.1.2.1 Dissolution System
      • 7.3.1.2.2 Dissolution Accessories
    • 7.3.1.3 Top Competitors
    • 7.3.1.4 Target Customers/End Users
    • 7.3.1.5 Analyst View
  • 7.3.2 Merck KGaA
    • 7.3.2.1 Overview
    • 7.3.2.2 Top Products
      • 7.3.2.2.1 Dissolution Accessories
    • 7.3.2.3 Top Competitors
    • 7.3.2.4 Target Customers/End Users
    • 7.3.2.5 Analyst View
  • 7.3.3 Thermo Fisher Scientific, Inc.
    • 7.3.3.1 Overview
    • 7.3.3.2 Top Products
      • 7.3.3.2.1 Dissolution System
    • 7.3.3.3 Top Competitors
    • 7.3.3.4 Target Customers/End Users
    • 7.3.3.5 Analyst View
  • 7.3.4 Danaher (Cytiva)
    • 7.3.4.1 Overview
    • 7.3.4.2 Top Products
      • 7.3.4.2.1 Dissolution Accessories
    • 7.3.4.3 Top Competitors
    • 7.3.4.4 Target Customers/End Users
    • 7.3.4.5 Analyst View
  • 7.3.5 Catalent, Inc.
    • 7.3.5.1 Overview
    • 7.3.5.2 Top Products
      • 7.3.5.2.1 Dissolution System
    • 7.3.5.3 Top Competitors
    • 7.3.5.4 Target Customers/End Users
    • 7.3.5.5 Analyst View
  • 7.3.6 Distek, Inc.
    • 7.3.6.1 Overview
    • 7.3.6.2 Top Products
      • 7.3.6.2.1 Dissolution System
    • 7.3.6.3 Top Competitors
    • 7.3.6.4 Target Customers/End Users
    • 7.3.6.5 Analyst View
  • 7.3.7 Sotax
    • 7.3.7.1 Overview
    • 7.3.7.2 Top Products
      • 7.3.7.2.1 Dissolution System
      • 7.3.7.2.2 Pharma Services
    • 7.3.7.3 Top Competitors
    • 7.3.7.4 Target Customers/End Users
    • 7.3.7.5 Analyst View
  • 7.3.8 Almac Group
    • 7.3.8.1 Overview
    • 7.3.8.2 Top Products
      • 7.3.8.2.1 Dissolution Testing Equipment
    • 7.3.8.3 Top Competitors
    • 7.3.8.4 Target Customers/End Users
    • 7.3.8.5 Analyst View
  • 7.3.9 Teledyne Technologies Incorporated
    • 7.3.9.1 Overview
    • 7.3.9.2 Top Products
      • 7.3.9.2.1 Dissolution Accessories
    • 7.3.9.3 Top Competitors
    • 7.3.9.4 Target Customers/End Users
    • 7.3.9.5 Analyst View
• 7.4 Service Providers
  • 7.4.1 Charles River Laboratories International, Inc.
    • 7.4.1.1 Overview
    • 7.4.1.2 Services Offered
    • 7.4.1.3 Top Competitors
    • 7.4.1.4 Target Customers/End Users
    • 7.4.1.5 Analyst View
  • 7.4.2 Eurofins Scientific
    • 7.4.2.1 Overview
    • 7.4.2.2 Services Offered
    • 7.4.2.3 Top Competitors
    • 7.4.2.4 Target Customers/End Users
    • 7.4.2.5 Analyst View
  • 7.4.3 Intertek Group plc
    • 7.4.3.1 Overview
    • 7.4.3.2 Services Offered
    • 7.4.3.3 Top Competitors
    • 7.4.3.4 Target Customers/End Users
    • 7.4.3.5 Analyst View
  • 7.4.4 Avivia BV
    • 7.4.4.1 Overview
    • 7.4.4.2 Services Offered
    • 7.4.4.3 Top Competitors
    • 7.4.4.4 Target Customers/End Users
    • 7.4.4.5 Analyst View
  • 7.4.5 Boston Analytical
    • 7.4.5.1 Overview
    • 7.4.5.2 Services Offered
    • 7.4.5.3 Top Competitors
    • 7.4.5.4 Target Customers/End Users
    • 7.4.5.5 Analyst View